Objective: One of the factors affecting liver functions in open coronary surgery (CABG) of patients with metabolic syndrome (MS) may be the anesthetic drugs used. For this purpose, we investigated the effects of midazolam-based total intravenous anesthesia (TIVA) and sevoflurane-based inhalation anesthesia on liver functions and postoperative complications in patients with MS who wiould undergo open coronary bypass surgery. Method: A total f 76 patients were included in our study. A statistically significant difference was not found between the TIVA (n=38) and SEVO (n=38) groups in terms of gender, age, body mass index (BMI), Euroscore values, presence of preoperative comorbidity, blood product transfusion, postoperative complications, and 30-day mortality rates. (p>0.05). Preoperative and postoperative laboratory parameters, ALT, AST, LDH, and glucose values were comparable between both groups. Results: 76 patients were included in our study. There was a statistically significant difference between the TIVA (n=38) and SEVO (n=38) groups in terms of gender, age, body mass index (BMI), euroscore values, presence of preoperative comorbidity, blood product transfusion, postoperative complications, and 30-day mortality rates. There was no difference (p>0.05). When compared according to preoperative and postoperative laboratory parameters, ALT, AST, LDH, and glucose values were found similar in both groups. Conclusion: In our study, we found that TIVA and SEVO groups are not superior to each other in coronary bypass patients with metabolic syndrome. Studies investigating detailed parameters with more patients will be guiding for this issue